Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

March 7, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

1
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

2
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

3
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

4
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

5
September 22, 2023October 1, 2023

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • A study of mortality from Alzheimer’s disease & other dementias

How obesity affects the relationship between Brain and Body!

BRAFi-addicted melanoma cells: proteomics and phosphoproteomics profiling

A study of mortality from Alzheimer’s disease & other dementias
  • BiotechToday
  • World

A study of mortality from Alzheimer’s disease & other dementias

bioxone August 6, 2021August 5, 2021

Ananya Ghosal, MAKAUT(WB)

40-50 million people are suffering from Alzheimer’s and other dementias worldwide. Due to the tendency of population aging and population growth, the number may rise to 100 million people suffering from the disease by 2050. From the population-based epidemiological study, dementia has been underreported on death certificates, even after including all contributing conditions and other significant conditions. The reporting on dementia on death is related to the location of the death as the deaths mostly occur in long-term care centers like psychiatric hospitals rather than home or general hospitals.

The previous repetition of the Global Burden of Diseases (GBD) is the only available worldwide estimate of dementia mortality. GBD 2015 introduced a new methodology for the estimation of dementia mortality. From GBD 2015, 2016, 2017 estimation of excess mortality which was derived from countries as a cause of death per general dementia cases. The method presumes that excess mortality is dependent on heterogeneous general data and sparse and is constant over time and location.

Methods

  • Systematic review- In PubMed, there were 34 studies which were extracted. The data was heterogeneous and consist of (dementia, Alzheimer’s disease, and cognitive impairment).
  • Analysis- The excess risk of dementia death was analyzed using the Bayesian bias-reduction meta-regression model. The model is consisting of the study of heterogeneity and adds uncertainty from heterogeneity to the coefficient estimate. The control categories included smoking and alcohol consumption, more extensive cardiovascular disease factors such as cholesterol and blood pressure, educational attainment, and basic cardiovascular disease comorbidities.
  • Prevalence estimation- The Bayesian meta-regression tool i.e., DisMod MR-2.1 is used in non-fatal modeling for GBD. When the mortality is combined with the incidence data higher prevalence was reported.
  • Calculation of excess dementia death-The multiplication of attributed risk and prevalence is the calculation of excess death which shows the total number of excess dementia death. The individual who died due to dementia had clinical markers end-stage disease one year before death. The subtraction with end-stage disease markers in those without dementia from those with dementias shows the individuals who have died with end-stage, severe dementia.
  • Final calculation results-The proportions of those individuals who die with severe disease due to excess dementia and total excess dementia deaths give rise to the number of deaths due to dementia. The age-standardized rate was calculated by following World Population Standard for GBD. Aggregating the estimate from the detailed location was calculated to get a regional and global estimate.

Conclusion

In the year 2019, 1.55 million deaths were reported of end-stage dementia where the majority were women. Common comorbid conditions resulted in estimating excess mortality in those with dementia. Population aging is the main factor for increasing the number of dementia deaths which gives rise to the volume of dementia mortality. The current estimation method deleted all dependencies from the vital registration system. Meta-analytic methods were utilized to estimate global mortality due to dementia. To give more precise information on dementia mortality, the analysis should be strengthened.  

Also read: Human genome from the sediments of Georgia Cave

Reference: Nichols, E., & Vos, T. (2020). Estimating the global mortality from Alzheimer’s disease and other dementias: A new method and results from the Global Burden of Disease study 2019: Epidemiology / Prevalence, incidence, and outcomes of MCI and dementia. Alzheimer’s & Dementia, 16(S10). https://doi.org/10.1002/alz.042236

  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP
  • AI Literacy in Early Childhood Education: Challenges and Opportunities

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged age-standardized Alzheimer’s diseases Bayesian meta-regression tool dementias excess mortality heterogeneity mortality population aging population growth

3 thoughts on “A study of mortality from Alzheimer’s disease & other dementias”

  1. Rahul Pal says:
    August 6, 2021 at 5:12 pm

    Thanks for this knowledge ..

    Reply
  2. Pingback: Natural killer cells: Defence against self-destruction - BioXone
  3. Pingback: Are children of heavy drinkers more exposed to adversities? - BioXone

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • BiotechToday
  • World

BRAFi-addicted melanoma cells: proteomics and phosphoproteomics profiling

bioxone August 6, 2021

Husna, Amity University Kolkata What is a BRAF inhibitor and what is its role? BRAF is a gene that is present on chromosome 7q34. It encodes a protein that has the ability to regulate the MAP kinase/ERKs-signaling pathway. These pathways have a crucial role in regulating cell division, differentiation, and the growth and proliferation of […]

BRAFi

Related Post

  • BiotechToday
  • World

EMT and MET in embryonic development

bioxone July 25, 2021July 24, 2021

Husna, Amity University Kolkata The development of an embryo depends on the transition between epithelial cells and mesenchyme. Epithelial cells are found in the lining of cavities, organs, and vessels in the body whereas mesenchymal cells are undifferentiated cells that can differentiate into any type of cells in the body at any time and give […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Novel cell membrane model- a step to uncover protein regulation

bioxone September 27, 2020September 27, 2020

Shrestha Dutta, Amity University Kolkata The cell membrane is fundamentally comprised of two types of biomolecules: lipids and proteins. By building up a novel sort of membrane model, a group of researchers led by Vanderbilt University were capable to show that the shape and role of a protein can be transformed by exposing to various […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • India

SIGN TO START PHASE 1 HUMAN TRIAL OF “ANTISERA”-DCGI

bioxone October 7, 2020October 7, 2020

Aishila Kar, Amity University Kolkata ICMR officials said on Tuesday that The Drugs Controller General of India has given authorization for conducting Phase-1 human clinical trial for an “antisera” that was developed by injecting inactivated SARS-CoV-2 in horses and can be a treatment for COVID-19. The Indian Council of Medical Research (ICMR) in alliance with a Hyderabad-based vaccine maker […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Exogenous Klotho as a Cognition Booster in Aging Primates

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy